This is the authors' abstract. We don't add key points for this paper.
infections are emerging in cystic fibrosis patients, and treatment success rate in these patients is only 33% due to extreme antibiotic resistance. Thus, new treatment options are essential. An interesting target could be Lsr2, a nucleoid-associated protein involved in mycobacterial virulence. Zafirlukast is a Food and Drug Administration (FDA)-approved drug against asthma that was shown to bind Lsr2. In this study, zafirlukast treatment is shown to reduce
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Niet et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: